You are here: Industry Insights > EpiVax

News List

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review PRNewswire
December 07, 2024
EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth.
EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants prnasia
December 01, 2021
Today EpiVax, Inc. ("EpiVax") confirmed that the company's EPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. ("EVT")...
Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax prnasia
July 07, 2021
EpiVax, Inc. is pleased to announce that Dr. Amy Rosenberg is leaving the FDA's Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics.
EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19 prnewswire
January 04, 2021
EpiVax and EpiVax Therapeutics provide an update on the advancement of their peptide-based COVID-19 vaccine, EPV-CoV-19.
Intravacc and EpiVax to develop Covid-19 vaccine candidate pharmaceutical-technology
June 04, 2020
Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm EpiVax to advance a Covid-19 vaccine candidate.
Immunomic partners EpiVax and PharmaJet on Covid-19 vaccine pharmaceutical-technology
April 14, 2020
Biotechnology firm Immunomic Therapeutics has partnered with EpiVax and PharmaJet to develop a vaccine candidate against Covid-19 infection.
EpiVax partners with UGA researcher on Covid-19 vaccine pharmaceutical-technology
March 09, 2020
EpiVax has partnered with University of Georgia (UGA) researcher Ted Ross for the development of a vaccine against Covid-19 caused by the coronavirus.
EpiVax Accelerates COVID-19 Vaccine Development americanpharmaceuticalreview
March 06, 2020
EpiVax announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia’s Ted Ross (Director, Center for Vaccines and Immunology (CVI)).
EpiVax and GAIA Vaccine Foundation Celebrate Women's Achievements Throughout History and Across Nati prnasia
March 12, 2018
EpiVax Inc., ("EpiVax") an innovative Rhode Island-based biotechnology company, has a lot to celebrate on International Women's Day.
EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology prnasia
September 26, 2017
EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc.

Previous page 1 2 Next page